Analyst Price Targets — CAH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 10:22 am | — | Barclays | $258.00 | $224.82 | TheFly | Cardinal Health price target raised to $258 from $243 at Barclays |
| February 10, 2026 11:36 am | — | Wells Fargo | $256.00 | $225.76 | TheFly | Cardinal Health price target raised to $256 from $237 at Wells Fargo |
| February 6, 2026 3:43 pm | — | Morgan Stanley | $255.00 | $229.63 | TheFly | Cardinal Health price target raised to $255 from $245 at Morgan Stanley |
| February 6, 2026 2:43 pm | — | Robert W. Baird | $252.00 | $228.78 | TheFly | Cardinal Health price target raised to $252 from $250 at Baird |
| February 6, 2026 1:14 pm | Kevin Caliendo | UBS | $260.00 | $228.63 | TheFly | Cardinal Health price target raised to $260 from $250 at UBS |
| February 6, 2026 12:33 pm | Steven Valiquette | Mizuho Securities | $235.00 | $227.18 | TheFly | Cardinal Health price target raised to $235 from $222 at Mizuho |
| February 5, 2026 7:21 pm | Elizabeth Anderson | Evercore ISI | $260.00 | $227.18 | StreetInsider | Cardinal Health (CAH) PT Raised to $260 at Evercore ISI |
| January 29, 2026 12:20 pm | Erin Wright | Morgan Stanley | $245.00 | $210.39 | TheFly | Cardinal Health price target raised to $245 from $224 at Morgan Stanley |
| January 14, 2026 2:33 pm | Eric Coldwell | Robert W. Baird | $250.00 | $211.98 | TheFly | Cardinal Health price target raised to $250 from $232 at Baird |
| January 13, 2026 7:50 pm | Michael Cherny | Leerink Partners | $240.00 | $208.24 | TheFly | Cardinal Health price target raised to $240 from $230 at Leerink |
Latest News for CAH
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
The 2025 Q4 earnings season is pretty much over following the highly-awaited NVIDIA release. Throughout the period, these three releases have stood out.
Cozad Asset Management Inc. lifted its position in Cardinal Health, Inc. (NYSE: CAH) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,266 shares of the company's stock after purchasing an additional 6,185 shares during the quarter.
New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains. DUBLIN, Ohio, Feb. 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.